Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China , Qingdao, 266003 Shandong, China.
J Med Chem. 2013 Nov 27;56(22):9057-70. doi: 10.1021/jm400930e. Epub 2013 Nov 14.
A novel series of permethyl ningalin B analogues were synthesized and evaluated for their P-glycoprotein (P-gp)-modulating activities in a P-gp-overexpressing breast cancer cell line (LCC6MDR). Compounds 35 and 37, which possess one methoxy group and one benzyloxy group at aryl ring C, displayed the most potent P-gp-modulating activity. A 1 μM concentration of 35 and 37 resensitized LCC6MDR cells toward paclitaxel by 42.7-fold, with respective EC50 values of 93.5 and 110.0 nM. Their mechanism of P-gp modulation is associated with an increase in intracellular drug accumulation. Their advantages also include low cytotoxicity (IC50 for L929 fibroblast >100 μM) and high therapeutic indexes (>909 after normalization with their EC50 values). 35 is not a substrate of P-gp. They are potentially dual-selective modulators for both P-gp and breast cancer resistance protein transporters. The present study demonstrates that these new compounds can be employed as effective and safe modulators of P-gp-mediated drug resistance in cancer cells.
一系列新型的全甲基宁巴林 B 类似物被合成,并在 P-糖蛋白(P-gp)过表达的乳腺癌细胞系(LCC6MDR)中评估其对 P-gp 的调节活性。在芳环 C 上具有一个甲氧基和一个苄氧基的化合物 35 和 37 显示出最强的 P-gp 调节活性。化合物 35 和 37 在 1μM 浓度下使 LCC6MDR 细胞对紫杉醇的敏感性增加了 42.7 倍,其 EC50 值分别为 93.5 和 110.0 nM。它们对 P-gp 的调节作用与其增加细胞内药物积累有关。它们的优点还包括低细胞毒性(对 L929 成纤维细胞的 IC50 >100 μM)和高治疗指数(在与 EC50 值归一化后 >909)。化合物 35 不是 P-gp 的底物。它们可能是 P-gp 和乳腺癌耐药蛋白转运体的双重选择性调节剂。本研究表明,这些新化合物可作为有效和安全的调节剂,用于调节癌细胞中 P-gp 介导的药物耐药性。